Science & Innovation Theaters

AMCP’s Science & Innovation Theaters provide a structured focus for participants to gain information on specific products, therapeutic areas and/or disease states in presentations provided by company designated presenters. Theaters take place in The Expo and do not compete with any other official AMCP functions.

In 2017, AMCP Science & Innovation Theaters included pre-approval information exchange sessions. For more information on the guidelines around pre-approval information exchange, click here.

Wednesday, April 25

Theater #1



Clinical and Economic Considerations for a MAT Option

Although medication-assisted therapy (MAT) is recommended as effective treatment for opioid dependence, its use has not kept pace with that of opioid dependence diagnoses. A MAT option associated with lower healthcare utilization and costs will be discussed. New studies regarding comparable efficacy, upon initiation of therapy, of some MAT options will also be reviewed.


Genie L. Bailey, M.D.
Diplomate, American Board of Addiction Medicine
Clinical Associate Professor of Psychiatry and Human Behavior
Warren Alpert Medical School of Brown University



Boehringer Ingelheim Pharmaceuticals, Inc.

Medical Benefit Biosimilars: The Next Opportunity for Cost Savings at Your Organization

The biosimilar pipeline is expected to ramp up with several key medical benefit biologic patents expiring in the next few years, representing a new opportunity for health plans and other stakeholders. We invite you to learn about barriers that could affect uptake of medical benefit biosimilars, how to incorporate these products into your organization, and strategies to encourage uptake through your physician network.


Bruce A. Feinberg, DO
Vice President Clinical Affairs and Chief Medical Officer at Cardinal Health

Edmund Pezalla, MD, MPH
Former Vice President and National Medical Director for Pharmaceutical Policy and Strategy at Aetna


Theater #2


Amgen, Inc.

Migraine – More Than Just a Headache:  Exploring the Burden, Management, and Costs

Migraine is a long-term neurological disease with underlying pathophysiology that is associated with physical and functional burden.1-4 Migraine affects many individuals in the US, with varying severity, often in their prime working years4. Optimizing migraine management starts with an accurate diagnosis and depending on disease severity, it may be managed using either acute or preventive medication, or both.5,6 If not adequately controlled, migraine can increase direct costs related to health resource utilization.7 Learn more about the burden, management, and cost of migraine at our Science and Innovation Theater.

  1. Buse D, et al. Neurology. 2015;84(14 Suppl):P5.039.
  2. 2. Russo AF. Annu Rev Pharmacol Toxicol. 2015;55:533–552. 3.
  3. Lipton RB, et al. Cephalalgia. 2003;23:429–440,
  4. 4. Lipton RB, et al. Neurology. 2007;63:343–349.
  5. 5. Headache Classification Committee of the International Headache Society (IHS). Cephalalgia. 2013;33:629–808.
  6. 6. Silberstein SD. Continuum (Minneap Minn). 2015;21(4 Headache):973–989.
  7. 7.Messali A, et al. Headache. 2016;56:306–322


Richard G. Wenzel, PharmD, CPPS
Clinical Pharmacist
Diamond Headache Clinic Inpatient Unit



Amgen, Inc.

Understanding the Value of Repatha® (evolocumab)

The value of innovative pharmaceuticals has been under debate given the rising costs in the US healthcare system. This presentation highlights Repatha® (evolocumab) and discusses important context regarding the value of Repatha® in clinical practice.


President, ASPC




Clinical Overview of FASENRA™(benralizumab):  A New Biologic for the Add-on Maintenance Treatment of Severe Asthma with an Eosinophilic Phenotype

This presentation provides an review of the product profile for FASENRA including:

  • The quantification and clinical characteristics of patients with severe eosinophilic asthma
  • The unique mechanism of action of FASENRA as the first and only monoclonal antibody for severe eosinophilic asthma that targets the interleukin-5 receptor alpha (IL-5Rα). The clinical data that demonstrated the efficacy and safety of FASENRA in patients with an eosinophilic phenotype


Michael E Wechsler, MD
Director, Asthma Program
Professor of Medicine
Division of Pulmonary, Critical Care & Sleep Medicine
National Jewish Health, Denver, CO


Thursday, April 26

Theater #1



Migraine Presentation: Update on Disease, New Therapies, and Real-World Clinical Evidence

This Migraine Education Program will address a range of emerging issues relevant to managed care practice.  Carla McSpadden, RPh, CGP will cover important changes in the understanding of migraine pathophysiology, focusing on structural and functional changes.  McSpadden will highlight epidemiologic data on the scope and distribution of migraine with an emphasis on chronic migraine, discuss real-world evidence of Botox, and cover the newest therapeutic advances to prepare pharmacists for what is to come in terms of novel treatments for migraine patients.


Carla McSpadden, RPh, CGP
Director, Scientific Payer Engagement




What Lies Behind the Psoriatic Arthritis ICD Code?

This presentation explores the disease manifestations of Psoriatic Arthritis (PsA) and their effects on patients, challenging us to look past the billing code and recognize the complexity of this multifaceted disease. Often viewed through the lenses of rheumatoid arthritis, this spondyloarthropathy is quite distinct and is characterized by involvement in the following domains: skin and nail psoriasis, peripheral arthritis, axial disease, dactylitis, and enthesitis. As the knowledge on PsA pathophysiology has evolved, recognizing these manifestations has become increasingly important, and can ensure appropriate patient management.


Dr Joseph F. Merola, MD, MMSc
Assistant Professor, Harvard Medical School
Director, Clinical Unit for Research Innovation and Trials (CUReIT), Dermatology
Co-Director, Center for Skin and Related Musculoskeletal Diseases
Dept of Dermatology and Dept of Medicine, Division of Rheumatology
Associate Program Director, Combined Medicine-Dermatology Residency Program
Brigham and Women’s Hospital, Boston, MA

Theater #2


AbbVie Medical Affairs*

Investigational Treatments in Rheumatology and Dermatology*

  • This presentation will provide a clinical overview of Upadacitinib and Risankizumab, including phase III clinical trial data. This information is intended to assist payors in planning and budgeting for future coverage and/or reimbursement decisions.
  • Upadacitinib and Risankizumab are both investigational products currently in phase III development.  The safety or effectiveness of Upadacitinib and Risankizumab and its uses have not been established or approved by the FDA
  • In compliance with existing FDA guidance, attendance will be limited to a “Payor” audience-this audience includes payors, formulary committees (e.g., pharmacy and therapeutics committees), drug information centers, technology assessment panels, pharmacy benefit managers, and other multidisciplinary entities that review scientific and technology assessments to make drug selection formulary management, and/or coverage and reimbursement decisions on a population basis for health care organizations. To Pre-Register for this event, please click here


Cynthia Holmes, PharmD
Scientific Director Dermatology

Casey Schlacher, RN
Scientific Director Rheumatology




Clinical Advancements in Gene Replacement Therapy*

This presentation will describe the clinical advancements made in gene replacement therapy with a focus on a nonreplicating adeno-associated virus vector carrying a self-complimentary SMN transgene (sc.AAV9.CB.SMN [self-complementary adeno-associated viral serotype 9]) currently in clinical studies for spinal muscular atrophy (SMA).


Samiah Al-Zaidy, MD
Medical Consultant for AveXis


* Subject to federal laws and regulations, attendance at certain sessions is restricted to payors, formulary committee, or other similar entity representatives with knowledge and expertise in the area of health care economic analysis, carrying out responsibilities for the selection of drugs for coverage or reimbursement. For more information, visit our website.